{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T21:57:31Z","timestamp":1773266251162,"version":"3.50.1"},"reference-count":37,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,6,3]],"date-time":"2021-06-03T00:00:00Z","timestamp":1622678400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neoplasia"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1016\/j.neo.2021.06.002","type":"journal-article","created":{"date-parts":[[2021,7,8]],"date-time":"2021-07-08T07:40:08Z","timestamp":1625730008000},"page":"783-791","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Plasma proteome alterations by MAPK inhibitors in BRAF-mutated metastatic cutaneous melanoma"],"prefix":"10.1016","volume":"23","author":[{"given":"Haris","family":"Baba\u010di\u0107","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hanna","family":"Eriksson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Pernemalm","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.neo.2021.06.002_bib0001","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1038\/nature00766","article-title":"Mutations of the BRAF gene in human cancer","volume":"417","author":"Davies","year":"2002","journal-title":"Nature"},{"key":"10.1016\/j.neo.2021.06.002_bib0002","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1056\/NEJMoa1904059","article-title":"Five-year outcomes with dabrafenib plus trametinib in metastatic melanoma","volume":"381","author":"Robert","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.neo.2021.06.002_bib0003","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1158\/1078-0432.CCR-18-4180","article-title":"Extended 5-year follow-up results of a phase Ib study (BRIM7) of vemurafenib and cobimetinib in BRAF-mutant melanoma","volume":"26","author":"Ribas","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.neo.2021.06.002_bib0004","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.ejca.2019.11.016","article-title":"Update on tolerability and overall survival in COLUMBUS: landmark analysis of a randomised phase 3 trial of encorafenib plus binimetinib vs vemurafenib or encorafenib in patients with BRAF V600-mutant melanoma","volume":"126","author":"Ascierto","year":"2020","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.neo.2021.06.002_bib0005","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1056\/NEJMoa1910836","article-title":"Five-year survival with combined nivolumab and ipilimumab in advanced melanoma","volume":"381","author":"Larkin","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.neo.2021.06.002_bib0006","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1001\/jamaoncol.2020.2288","article-title":"Association of BRAF V600E\/K mutation status and prior BRAF\/MEK Inhibition with pembrolizumab outcomes in advanced melanoma: pooled analysis of 3 clinical trials","volume":"6","author":"Puzanov","year":"2020","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.neo.2021.06.002_bib0007","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1002\/cncr.28620","article-title":"Outcomes of patients with metastatic melanoma treated with immunotherapy prior to or after BRAF inhibitors","volume":"120","author":"Ackerman","year":"2014","journal-title":"Cancer"},{"key":"10.1016\/j.neo.2021.06.002_bib0008","doi-asserted-by":"crossref","first-page":"144","DOI":"10.3109\/07357907.2014.885984","article-title":"Sequential treatment with ipilimumab and BRAF inhibitors in patients with metastatic melanoma: data from the Italian cohort of the ipilimumab expanded access program","volume":"32","author":"Ascierto","year":"2014","journal-title":"Cancer Invest"},{"key":"10.1016\/j.neo.2021.06.002_bib0009","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1016\/S1470-2045(16)30578-2","article-title":"Factors predictive of response, disease progression, and overall survival after dabrafenib and trametinib combination treatment: a pooled analysis of individual patient data from randomised trials","volume":"17","author":"Long","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.neo.2021.06.002_bib0010","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.ejca.2017.05.033","article-title":"Three-year pooled analysis of factors associated with clinical outcomes across dabrafenib and trametinib combination therapy phase 3 randomised trials","volume":"82","author":"Schadendorf","year":"2017","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.neo.2021.06.002_bib0011","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/nmeth.2732","article-title":"HiRIEF LC-MS enables deep proteome coverage and unbiased proteogenomics","volume":"11","author":"Branca","year":"2014","journal-title":"Nat Methods"},{"key":"10.1016\/j.neo.2021.06.002_bib0012","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.41608","article-title":"In-depth human plasma proteome analysis captures tissue proteins and transfer of protein variants across the placenta","volume":"8","author":"Pernemalm","year":"2019","journal-title":"Elife"},{"issue":"1","key":"10.1016\/j.neo.2021.06.002_bib0013","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2019-000204","article-title":"In-depth plasma proteomics reveals increase in circulating PD-1 during anti-PD-1 immunotherapy in patients with metastatic cutaneous melanoma","volume":"8","author":"Baba\u010di\u0107","year":"2020","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.neo.2021.06.002_bib0014","doi-asserted-by":"crossref","first-page":"e95192","DOI":"10.1371\/journal.pone.0095192","article-title":"Homogenous 96-plex PEA immunoassay exhibiting high sensitivity, specificity, and excellent scalability","volume":"9","author":"Assarsson","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.neo.2021.06.002_bib0015","first-page":"93","article-title":"The eighth edition AJCC cancer staging manual: continuing to build a bridge from a population-based to a more \u201cpersonalized\u201d approach to cancer staging","volume":"67","author":"Amin","year":"2017","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.neo.2021.06.002_bib0016","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1038\/s41591-019-0673-2","article-title":"Undulating changes in human plasma proteome profiles across the lifespan","volume":"25","author":"Lehallier","year":"2019","journal-title":"Nat Med"},{"key":"10.1016\/j.neo.2021.06.002_bib0017","doi-asserted-by":"crossref","first-page":"901","DOI":"10.15252\/msb.20167357","article-title":"Proteomics reveals the effects of sustained weight loss on the human plasma proteome","volume":"12","author":"Geyer","year":"2016","journal-title":"Mol Syst Biol"},{"key":"10.1016\/j.neo.2021.06.002_bib0018","doi-asserted-by":"crossref","first-page":"786","DOI":"10.15252\/msb.20145728","article-title":"Quantitative variability of 342 plasma proteins in a human twin population","volume":"11","author":"Liu","year":"2015","journal-title":"Mol Syst Biol"},{"key":"10.1016\/j.neo.2021.06.002_bib0019","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2020.102854","article-title":"Facets of individual-specific health signatures determined from longitudinal plasma proteome profiling","volume":"57","author":"Dodig-Crnkovi\u0107","year":"2020","journal-title":"EBioMedicine"},{"key":"10.1016\/j.neo.2021.06.002_bib0020","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.annonc.2019.09.005","article-title":"Elevated baseline serum PD-1 or PD-L1 predicts poor outcome of PD-1 inhibition therapy in metastatic melanoma","volume":"31","author":"Ugurel","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.neo.2021.06.002_bib0021","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1038\/labinvest.2016.132","article-title":"Immunomodulating property of MAPK inhibitors: From translational knowledge to clinical implementation","volume":"97","author":"Mandal\u00e0","year":"2017","journal-title":"Lab Investig"},{"issue":"2","key":"10.1016\/j.neo.2021.06.002_bib0022","doi-asserted-by":"crossref","first-page":"287","DOI":"10.3390\/cancers12020287","article-title":"Chemokines and their receptors: multifaceted roles in cancer progression and potential value as cancer prognostic markers","volume":"12","author":"Do","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.neo.2021.06.002_bib0023","doi-asserted-by":"crossref","first-page":"6623","DOI":"10.18632\/oncotarget.27304","article-title":"The multifaceted anti-cancer effects of BRAF-inhibitors","volume":"10","author":"Croce","year":"2019","journal-title":"Oncotarget"},{"issue":"7","key":"10.1016\/j.neo.2021.06.002_bib0024","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12071823","article-title":"BRAF Inhibitors: molecular targeting and immunomodulatory actions","volume":"12","author":"Proietti","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.neo.2021.06.002_bib0025","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1172\/JCI66236","article-title":"Host immunity contributes to the anti-melanoma activity of BRAF inhibitors","volume":"123","author":"Knight","year":"2013","journal-title":"J Clin Invest"},{"key":"10.1016\/j.neo.2021.06.002_bib0026","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1084\/jem.20051848","article-title":"The BRAF-MAPK signaling pathway is essential for cancer-immune evasion in human melanoma cells","volume":"203","author":"Sumimoto","year":"2006","journal-title":"J Exp Med"},{"key":"10.1016\/j.neo.2021.06.002_bib0027","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1158\/1078-0432.CCR-12-1630","article-title":"BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma","volume":"19","author":"Frederick","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.neo.2021.06.002_bib0028","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.4049\/jimmunol.1302616","article-title":"Dynamics of chemokine, cytokine, and growth factor serum levels in BRAF-mutant melanoma patients during BRAF inhibitor treatment","volume":"192","author":"Wilmott","year":"2014","journal-title":"J Immunol"},{"key":"10.1016\/j.neo.2021.06.002_bib0029","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1158\/1078-0432.CCR-11-2479","article-title":"Selective BRAF inhibitors induce marked T-cell infiltration into human metastatic melanoma","volume":"18","author":"Wilmott","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.neo.2021.06.002_bib0030","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1111\/j.1755-148X.2009.00554.x","article-title":"The good and the bad of chemokines\/chemokine receptors in melanoma","volume":"22","author":"Richmond","year":"2009","journal-title":"Pigment Cell Melanoma Res"},{"key":"10.1016\/j.neo.2021.06.002_bib0031","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1007\/s00262-012-1389-z","article-title":"Inhibition of both BRAF and MEK in BRAF(V600E) mutant melanoma restores compromised dendritic cell (DC) function while having differential direct effects on DC properties","volume":"62","author":"Ott","year":"2013","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.neo.2021.06.002_bib0032","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.phrs.2018.08.019","article-title":"Immunomodulatory effects of BRAF and MEK inhibitors: implications for melanoma therapy","volume":"136","author":"Kuske","year":"2018","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.neo.2021.06.002_bib0033","doi-asserted-by":"crossref","first-page":"4428","DOI":"10.18632\/oncotarget.6599","article-title":"Overcoming melanoma resistance to vemurafenib by targeting CCL2-induced miR-34a, miR-100 and miR-125b","volume":"7","author":"Vergani","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.neo.2021.06.002_bib0034","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.cell.2019.12.023","article-title":"Quantitative proteomics of the cancer cell line encyclopedia","volume":"180","author":"Nusinow","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.neo.2021.06.002_bib0035","doi-asserted-by":"crossref","first-page":"87","DOI":"10.3109\/00365529409090443","article-title":"Serum pancreas-specific protein in acute pancreatitis: Its clinical utility in comparison with serum amylase","volume":"29","author":"Chen","year":"1994","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.neo.2021.06.002_bib0036","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1056\/NEJMc1302338","article-title":"Hepatotoxicity with combination of vemurafenib and ipilimumab","volume":"368","author":"Ribas","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.neo.2021.06.002_bib0037","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1038\/s41591-019-0448-9","article-title":"Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma","volume":"25","author":"Ascierto","year":"2019","journal-title":"Nat Med"}],"container-title":["Neoplasia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1476558621000427?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1476558621000427?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T13:07:53Z","timestamp":1761484073000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1476558621000427"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8]]},"references-count":37,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["S1476558621000427"],"URL":"https:\/\/doi.org\/10.1016\/j.neo.2021.06.002","relation":{},"ISSN":["1476-5586"],"issn-type":[{"value":"1476-5586","type":"print"}],"subject":[],"published":{"date-parts":[[2021,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Plasma proteome alterations by MAPK inhibitors in BRAFV600-mutated metastatic cutaneous melanoma","name":"articletitle","label":"Article Title"},{"value":"Neoplasia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neo.2021.06.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}